RxDoctor Payments Data

Jeffrey Taylor, NP

Family · Johnson City, TNNPI 1518329028

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $18,910 of the $24,559 with a category attached, or 77.0%. It is spread thinly across 60 manufacturers, the largest accounting for just 12.9% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$24,559in general payments, 2019–2025

Across 930 payments — averaging $26.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$3K
  • Johnson & Johnson$2K
  • G1 Therapeutics, Inc.$1K
  • AstraZeneca$1K
  • Merck$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • plus $14K from 54 others

What the payments were for

  • Speaking & faculty fees$1,0004%
  • Travel & lodging$2041%
  • Food & beverage$18,91077%
  • Education$2,2489%
  • Other$2,1969%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis72$3,168
Johnson & Johnson(2 entities)69$1,738
G1 Therapeutics, Inc.9$1,492
AstraZeneca(2 entities)63$1,483
Merck54$1,361
E.r. Squibb & Sons, L.L.C.71$1,287
Daiichi Sankyo Inc.43$957
Incyte Corporation37$907
Astellas Pharma US Inc34$830
Bristol Myers Squibb26$679
Lilly USA, LLC33$637
Amgen27$627
Genentech USA, Inc.30$571
Sanofi27$568
Pfizer29$558
Seagen Inc.16$503
AbbVie13$492
Eisai Inc.20$465
Takeda Pharmaceuticals U.S.A., Inc.16$452
Regeneron Healthcare Solutions, Inc.15$451
Bayer24$413
Gilead(2 entities)18$365
Beigene USA, Inc.15$350
Exelixis Inc.12$315
AVEO Pharmaceuticals, Inc.8$287
Ipsen Biopharmaceuticals, Inc9$239
GSK7$238
Sobi, Inc5$212
EMD Serono, Inc.10$194
Tersera Therapeutics LLC8$161
Sanofi-aventis U.S. LLC2$160
Epizyme, Inc.5$154
Jazz Pharmaceuticals Inc.4$145
Mirati Therapeutics, Inc.4$140
Boehringer Ingelheim6$130
Genmab U.S., Inc.6$127
Array Biopharma Inc9$124
Pharmacyclics LLC, An Abbvie Company7$116
Morphosys, US Inc.4$108
Beone Medicines USA, Inc.5$105
Myriad Genetic Laboratories, Inc.7$103
Puma Biotechnology, Inc.1$89
Karyopharm Therapeutics Inc.4$84
Intuitive Surgical1$82
Taiho Oncology, Inc.5$81
Rigel Pharmaceuticals, Inc.4$71
Iovance Biotherapeutics, Inc.2$58
Pharmaessentia USA Corporation2$50
Kyowa Kirin, Inc.3$48
Servier Pharmaceuticals LLC2$47
Caris MPI, Inc.2$41
Verity Pharmaceuticals Inc.2$39
Geron Corporation2$39
Saluda Medical Americas, Inc.1$37
Agios Pharmaceuticals, Inc.2$33
Apellis Pharmaceuticals, Inc.2$33
Tempus AI, Inc1$29
Foundation Medicine, Inc.1$27
Alnylam Pharmaceuticals Inc.1$26
Corcept Therapeutics1$26

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,559 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$114,894
Medicare patients
117
Services billed
5,628

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban28$20,810
Ondansetron OdtOndansetron44$2,297
Exemestane12$1,602
Tamoxifen Citrate27$1,130
ValacyclovirValacyclovir Hcl16$1,082
Letrozole44$880
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen15$714
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen14$396
Omeprazole33$382
Ciprofloxacin Hcl12$165
Levothyroxine Sodium28$157
Alendronate Sodium23$94
Metformin Hcl ErMetformin Hcl12$90
Atorvastatin Calcium15$90
Pantoprazole Sodium12$78

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$558$20,81028 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.

Other family in Johnson City

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →